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Abstract
Development and function of the human heart depend on the dynamic control of tissue-specific 
gene expression by distant-acting transcriptional enhancers. To generate an accurate genome-wide 
map of human heart enhancers, we used an epigenomic enhancer discovery approach and 
identified ∼6,200 candidate enhancer sequences directly from fetal and adult human heart tissue. 
Consistent with their predicted function, these elements were markedly enriched near genes 
implicated in heart development, function and disease. To further validate their in vivo enhancer 
activity, we tested 65 of these human sequences in a transgenic mouse enhancer assay and 
observed that 43 (66%) drove reproducible reporter gene expression in the heart. These results 
support the discovery of a genome-wide set of non-coding sequences highly enriched in human 
heart enhancers which is likely to facilitate down-stream studies of the role of enhancers in 
development and pathological conditions of the heart.
Heart disease is a leading cause of morbidity and mortality in both children and adults and 
significantly depends on genetic factors 1-5. Genome-wide association studies indicate that 
variation in non-coding sequences, including distant-acting transcriptional enhancers, affects 
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the susceptibility to many types of human disease 6-10. However, the possible role of 
enhancers in heart disease has been difficult to evaluate due to the lack of a human cardiac 
enhancer catalogue. Mapping of enhancer-associated epigenomic marks via chromatin 
immunoprecipitation coupled to massively parallel sequencing (ChIP-seq) represents a 
conservation-independent strategy to discover tissue-specific enhancers 11-14. It has 
previously been shown that genome-wide binding profiles of an enhancer-associated co-
activator protein, p300, in mouse heart tissue can correctly predict the genomic location of 
heart enhancers in the mouse genome 15. However, the sequences identified by this 
approach tend to be poorly conserved in evolution, suggesting that mouse-derived ChIP-seq 
data sets are of limited value for accurate annotation of heart enhancers in the human 
genome.
To generate genome-wide maps of predicted cardiac enhancers in the human genome, we 
determined the occupancy of two enhancer-associated co-activator proteins in human fetal 
(gestational week 16) and adult heart. We performed chromatin immunoprecipitation with a 
pan-specific antibody that recognizes both p300 and the closely related CBP co-activator 
protein 16-18. Massively parallel sequencing and enrichment analysis 19 of the aligned 
sequences from fetal heart tissue identified 5,047 p300/CBP-bound regions (peaks) genome-
wide that were located at least 2.5kb from the nearest transcript start site (Fig. 1a/c, 
Supplementary Table 1, Supplementary Fig. 1, Methods). Likewise, 2,233 regions were 
identified from adult human heart. Nearly half of the adult human heart enhancer candidates 
(1,082; 48%) coincided with candidate enhancers derived from fetal human heart. In 
addition, many peaks identified in one of the samples exhibit read densities above 
background, but below the peak significance threshold in the respective other sample. In 
total, 4,257 (84%) of fetal peaks and 2,113 (95%) of adult peaks show significantly or sub-
significantly increased read densities in the adult and fetal data set, respectively. This 
remarkable overlap in data from the two samples suggests that many cardiac p300/CBP 
binding sites are maintained from prenatal stages of heart development into adulthood (Fig. 
1b, Supplementary Fig. 2). These results indicate that thousands of distal p300/CBP binding 
sites (candidate enhancers) exist in fetal and adult human heart tissue.
Tissue-specific enhancers typically act over distances of tens or hundreds of kilobases 9, 
therefore authentic cardiac enhancers are expected to be detectably enriched in the larger 
genomic vicinity of genes that are expressed and functional in the heart. To assess this, we 
examined the cardiac expression and function of genes located near the ChIP-seq-identified 
regions. First, we compared the genome-wide set of candidate enhancers to genome-wide 
gene expression data from human heart tissue. We observed a 4.7-fold enrichment in heart 
p300/CBP peaks within 2.5-10kb of the transcript start sites of genes highly expressed in 
fetal human heart (p < 1e-40, binomial distribution), with significant enrichment up to 200kb 
away from promoters (cumulative fold enrichment 2.6, p < 0.001, binomial distribution, Fig. 
2a). Enrichment was also observed for human adult candidate enhancers or when RNA 
polymerase II-binding to gene promoters was used as a complementary approach to identify 
active genes (Supplementary Note and Supplementary Figs. 3 and 4). In contrast, no 
enrichment of p300/CBP binding sites was observed near genes highly expressed in other 
tissues (Fig. 2b). Second, to examine if candidate cardiac enhancers are enriched near genes 
with known cardiac functions, we performed an unsupervised statistical enrichment analysis 
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of functional gene annotations 20. Candidate heart enhancers are indeed associated with 
genes that have been linked to cardiovascular functions in mouse deletion studies and by 
gene ontology (GO) annotations 21 (Table 1, Supplementary Table 2). These results indicate 
that candidate enhancers identified by p300/CBP binding in the human heart are enriched 
near genes that are expressed and functional in the cardiovascular system, supporting their 
function as human heart enhancers in the genome.
To assess the potential relevance of predicted heart enhancers to cardiac diseases, we 
focused on candidate enhancers located in the genomic vicinity of genes associated with 
different types of congenital and adult heart disorders. We compiled a panel of 73 genes 
used in genetic diagnosis of heart diseases and found that candidate heart enhancers are 
significantly enriched near these genes (Supplementary Fig. 5). We identified 81 human 
fetal heart candidate enhancers that are located within 50kb of 30 of these cardiac genes, an 
enrichment of 4.5-fold over what would be expected by chance (p < 7e-15, hypergeometric 
distribution, see Methods). These genes are associated with a variety of cardiac diseases, 
including conduction disorders (potassium channels KCNQ1 and KCNE2), 
cardiomyopathies (muscle structural proteins MYL2, ACTN2 and TNNC1), and congenital 
defects (cardiac transcription factors GATA4, NKX2.5 and TBX5) (Supplementary Table 3). 
To facilitate the study of genetic variation in candidate enhancers, we identified 1,546 
known single nucleotide polymorphisms (SNPs) within these 81 candidate enhancers 
(Supplementary Table 3). In addition, we have identified genetic variants in 11 candidate 
enhancers that have been linked to changes in expression of genes in human cell types 22 
(Supplementary Table 4). While in-depth studies will be required to clarify how these 
sequence variants affect the in vivo activity of individual enhancers, these data highlight the 
usefulness of a genome-wide set of heart enhancers as an entry-point for the functional 
exploration of non-coding enhancer variants contributing to cardiac disease.
It was previously shown that embryonic mouse heart enhancers tend to be poorly conserved 
in evolution 15, raising the possibility that many human heart enhancers might also be under 
weak evolutionary constraint. Comparison with previously published mouse enhancer data 
sets confirmed that human candidate heart enhancer sequences also tend to be under 
relatively weak evolutionary constraint 13,15,23 (Supplementary Fig. 6). Moreover, the vast 
majority of human peaks (86%) identified in this study were not predicted in previous 
computational screens combining evolutionary conservation with motif-based prediction of 
heart enhancers 24. These observations emphasize the limitations of comparative genomic 
and computational methods for the discovery of heart enhancers in the human genome.
In light of the apparently limited sequence conservation of human heart candidate enhancers, 
we also re-examined the utility of mouse-derived ChIP-seq data sets for accurate annotation 
of human heart enhancers. We performed p300/CBP ChIP-seq on mouse heart tissue at 
postnatal day 2, a stage at which the developmental progression and gene expression profile 
of the mouse heart is broadly similar to that of human fetal heart at gestational week 
16 25,26. Using identical methods as for human heart tissue, we identified 6,564 candidate 
enhancers (distal ChIP-seq peaks, Supplementary Table 1) and compared them to the human 
fetal candidate enhancer sets. We find that merely 21% of fetal human heart enhancer 
candidates coincided with significant peaks at the orthologous site in the mouse genome, 
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whereas the location of the majority of human peaks could not have been predicted from the 
mouse data set (Supplementary Fig. 7, Supplementary Note, Methods). While some 
candidate enhancers may have been missed in the mouse data set due to technical limitations 
of the approach, these observations suggest that lineage-specific differences in genome-wide 
enhancer architecture represent a major obstacle for the identification of human heart 
enhancers and highlight the value of performing ChIP-seq directly on human tissue samples.
To further validate and characterize the ChIP-seq-predicted human heart enhancers, we 
utilized a transgenic mouse enhancer assay that was previously demonstrated to be an 
effective approach to define the in vivo activity patterns of human and mouse 
enhancers 13,15,27,28. We tested 65 candidate human heart enhancers in transgenic mice at 
embryonic day 11.5 (e11.5). These candidates were selected blind to the identity of nearby 
genes, focusing on sequences that showed high-confidence p300/CBP-binding in the fetal 
heart data set. The selected regions were a sampling of sequences from all categories of 
evolutionary and functional conservation (Supplementary Tables 5 and 6). In total, 43 of 65 
(66%) tested sequences drove reproducible expression in the heart or in the vasculature; 
either exclusively (28, 43%) or as a part of reproducible compound patterns that included the 
heart (15, 23%) (Fig. 3, selected examples in Fig. 4, Supplementary Table 7). The in vivo 
validation rate of the tested human sequences was significantly higher than the frequency of 
in vivo heart enhancers among conserved sequences near heart-expressed genes or among 
enhancer predictions derived from human cell lines (Supplementary Table 8, Supplementary 
Figures 8 and 9) and similar to that of mouse-derived candidate heart enhancer sequences 
previously tested in this assay (compared to data sets described in ref. 15; Supplementary 
Fig. 9). While the tested human sequences in the present study were on average longer than 
the previously tested mouse sequences (3,719bp vs. 1,648bp, Supplementary Table 9), the 
predicted human candidate heart enhancers have overall robust cardiac activity and potential 
human-mouse species incompatibilities have only minor effects on the reproducibility of 
reporter patterns (Supplementary Table 10). Importantly, we did not observe significant 
differences in the reproducible activity of the tested elements between the different classes 
of conservation (Fig. 3b, p=0.9, Chi-square test). The reproducible activity of even weakly 
conserved human heart enhancers in this assay may be at least partly attributable to 
enrichment of the same transcription factor binding sites in human and mouse heart 
enhancer sequences (Supplementary Figure 10). The considerable validation rate in this 
first-pass screen at e11.5 suggests that the ChIP-seq data sets derived from human heart 
tissue identify a population of human non-coding sequences that are highly enriched for 
bona fide human heart enhancers.
To examine whether human ChIP-seq data can be used to predict in vivo heart enhancers 
beyond prenatal stages of development, we also studied sequences predicted to be enhancers 
active in the adult human heart in adult transgenic mice. In total, 41 of the 65 (63%) 
candidate enhancers tested at e11.5 are also bound by p300/CBP in the adult human heart 
and were therefore considered as adult human heart candidate enhancers (Supplementary 
Fig. 11). We selected eight sequences that had been validated as heart enhancers at e11.5 
and examined their in vivo activity patterns in four week-old (adult) transgenic mice. All 
eight enhancers showed reproducible activity in hearts from the adult animals, regardless of 
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their sequence and binding conservation (Supplementary Table 11). To explore the spatial 
activity of these enhancers, we examined transverse sections from representative whole-
mount stained embryos and longitudinal sections from adult hearts and annotated 
reproducible reporter staining patterns. While different enhancers drive expression to 
distinct subregions of the developing and adult heart, we observed a remarkable general 
concordance between the regions targeted by the same enhancer in the embryonic and adult 
heart in seven of the eight cases examined (Fig. 4 and Supplementary Fig. 12). These results 
further support that the ChIP-seq data sets obtained in this study correctly predict the 
genomic location of human non-coding sequences that are active developmental and adult 
heart enhancers in vivo.
Deciphering the gene regulatory architecture required for development and function of the 
human heart represents a daunting but pressing challenge. In the present study, we have used 
an epigenomic approach to identify a genome-wide set of several thousand putative human 
heart enhancers by performing ChIP-seq for the enhancer-associated proteins p300/CBP on 
human fetal and adult ex vivo heart tissue 11-14. Through transgenic mouse reporter 
experiments, we also demonstrated that the majority of these sequences are authentic in vivo 
heart enhancers. Importantly, comparison of these human-derived epigenomic data sets with 
ChIP-seq data from mouse heart tissue revealed that many heart enhancers are neither 
evolutionarily nor functionally conserved between human and mouse. Our studies 
demonstrate that even human heart enhancers whose sequence is not conserved in mice have 
robust cardiac activity in this assay, suggesting that mouse transcription factors are 
sufficiently similar to those of humans to correctly report the cis-regulatory function of 
poorly conserved human enhancers. The results from this study add an experimentally 
defined layer of functional annotation to the human genome and are expected to be critical 
for elucidating the role of distant-acting enhancer sequences in human heart disorders.
Data availability
All raw sequences and processed data from ChIP-seq experiments are publicly available 
from NCBI under accession numbers GSE32587. Complete in vivo data sets are available 
from the Vista Enhancer Browser at http://enhancer.lbl.gov
Methods
Human and mouse heart tissue collection and preparation
Adult heart tissue (ischemic, failing, male, age 45y, ejection fraction 31%) was obtained 
from a heart removed at the time of transplant at the University of California, San Francisco 
(UCSF) with the approval of the UCSF Committee for Human Research. Full informed 
consent was obtained from the transplant recipient prior to surgery. Cold cardioplegic 
solution was perfused antegrade prior to cardiectomy, and the explanted heart was placed 
immediately in ice-cold physiologic solution. Samples were cleaned rapidly of all epicardial 
fat, flash frozen in liquid nitrogen, and stored at −80°C. Fresh fetal heart tissues from 
gestational week 16 were obtained from ABR, Inc. (Alameda, CA) in compliance with 
applicable state and federal laws and with full informed consent. Postnatal day 2 mouse 
heart tissues were isolated and pooled from approximately 15 CD-1 strain mice. All 
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procedures of this study involving human and animal tissue samples were reviewed and 
approved by the respective institutional Human and Animal Regulatory Committees at 
Lawrence Berkeley National Laboratory.
Tissue samples were processed for ChIP and DNA sequencing as described previously 13,15 
except for the following modifications: following cross-linking in 1% formaldehyde, fresh 
samples were dissociated in a glass dounce homogenizer and frozen tissues were 
homogenized using a Polytron homogenizer. Chromatin was sheared using a Bioruptor 
(Diagenode) and immunoprecipitated using 40 ul anti-acetyl-CBP/p300 antibody (rabbit 
polyclonal #4771, Cell Signaling Technology) that recognizes these proteins in their active, 
acetylated state30,31 or 5 ug anti-RNA polymerase II antibody (mouse monoclonal ab817, 
Abcam).
Processing of ChIP-sequence data
Sequence reads (36 bp) were aligned to the reference genomes (NCBI build 36, hg18 and 
NCBI build 37, mm9) using bwa 32. Repetitively mapped and duplicate reads were excluded 
and alignments were extended to 300 bp to account for the estimated sequenced DNA 
fragment length. Cumulative genome-wide coverage of extended reads was calculated at 25 
bp resolution.
High confidence data sets of CBP/p300 bound regions were identified from the intersection 
of MACS 11 (version 1.4, with default settings except --bw=300 --p=1e-5 --mfold=10,30 --
llocal=20000 --off-auto --shiftsize=100) and the Grizzly Peak Fitting algorithm (http://
eisenlab.org/software/grizzly, modified from Capaldi et al. 19). Grizzly peaks with a 
separating gap of less than the length of either of the two peaks or by less than 1kb were 
merged into single regions. Peaks were scored and sorted based on maximal occupancy, as 
called by Grizzly. Bound regions mapped to unassembled chromosomal contigs, 
centromeric regions, telomeric regions, segmental duplications, as well as regions where 
>50% of the contributing reads originate in repeats were removed from further analyses as 
likely artifacts.
p300/CBP-bound regions were classified according to their proximity to transcription start 
sites of UCSC known genes 33. Regions within 2.5kb of the nearest transcript start site were 
defined as promoter peaks. The remaining peaks represent candidate distant-acting heart 
enhancers.
To assess the reproducibility of p300/CBP ChIP-seq, we performed ChIP-seq from a second 
human fetal heart sample. Enrichment of reads from human fetal heart ChIP-seq samples in 
the vicinity of candidate adult heart enhancers was performed using custom scripts. For 
comparison, a generic human input DNA sample was generated by combining 1 million 
randomly sampled reads from input DNA samples from each of 9 human cell lines, 
generated as part of the ENCODE project 34,35.
Enrichment of candidate enhancers near cardiovascular-related genes
Enrichment of human heart candidate enhancers near heart-expressed genes was determined 
by comparing the frequency of human heart candidate enhancers with the frequency of 
May et al. Page 6
Nat Genet. Author manuscript; available in PMC 2012 July 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
matched random regions near heart over- and under-expressed genes. Differentially 
expressed genes were identified using publicly available gene expression data from human 
fetal heart (GEO data set GSE1789, average expression across 5 ∼20wk normal fetal heart 
samples 36), human adult heart (http://www.cardiogenomics.org [retrieved October 2010], 
average expression across 32 ischemic human heart samples) and human non-heart tissues 
(http://www.affymetrix.com/Auth/support/downloads/demo_data/HG-U133_Plus_2.tissue-
mixture-data-set.apt-results.zip, average expression across ten non-heart tissues). Heart 
over- and under-expressed genes were identified by comparison with the non-heart tissue 
data set. Genes expressed at levels less than 100 in both heart and non-heart were excluded 
from further analysis. Heart over- and under-expressed genes were identified as the top 1000 
genes ranked by the ratio of expression in heart versus non-heart and non-heart versus heart, 
respectively. To determine the expected frequency of candidate enhancers near heart over- 
and under-expressed genes, matched randomized data sets were generated by moving each 
candidate enhancer to a random location on the same chromosome, excluding regions that 
fail the peak filtering procedure described above. Enrichment of candidate heart enhancers 
was determined by comparison with the average frequency of randomized regions over 
1,000 iterations.
Unsupervised enrichment analysis of gene annotation in the proximity of p300/CBP human 
fetal heart candidate enhancers was performed using Genomic Regions Enrichment of 
Annotations Tool (GREAT) 20. Enrichment of p300/CBP candidate enhancers near RNA 
polymerase II proximal peaks was determined by comparing the frequency of human heart 
candidate enhancers with the frequency of matching random regions near proximal RNA 
polymerase II proximal (<2.5Kb away from nearest transcription start site) peaks (RNA 
polymerase II peaks were called using the same method as for p300/CBP ChIP-seq).
The genetest@NIH database (http://www.ncbi.nlm.nih.gov/sites/GeneTests/) was used to 
identify 73 genes known to be involved in heart disease: CASQ2, GBA, LMNA, TNNT2, 
PSEN2, ACTA1, AGT, ACTN2, RYR2, SLC29A3, VCL, LDB3, ANKRD1, CSRP3, KCNQ1, 
ANO5, MYBPC3, MYL2, TBX5, ABCC9, PKP2, TMPO, SGCG, MYH6, MYH7, PSEN1, 
TGFB3, ACTC1, CAPN3, TPM1, TCAP, JUP, SGCA, ACE, DSC2, DSG2, TTR, FKRP, 
TNNI3, CFC1, TTN, DES, DYSF, JAG1, KCNE2, KCNE1, PPARG, TMEM43, AGTR1, 
DNAJC19, SCN5A, MYL3, TNNC1, CAV3, SGCB, MYOT, SGCD, NKX2-5, PLN, GJA1, 
EYA4, DSP, PRKAG2, GATA4, CHD7, TMEM70, FKTN, TRIM32, NOTCH1, LAMP2, 
FLNA, TAZ, DMD. The human heart candidate enhancer data set was intersected with the 
regions flanking 50kb downstream and upstream heart disease-associated genes using 
Galaxy server 37,38.
The list of SNPs and their locations was retrieved from dbSNP build 130 using the table 
function of UCSC Genome Browser 33,39.
The list of functional SNPs affecting gene expression in primary human cells was retrieved 
from ref. 22 and 1637 eQTL SNPs for three cell types of 75 individuals 22 were intersected 
with 5,047 fetal human heart candidate enhancers.
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Sequence constraint analyses
Evolutionary constraint of candidate enhancers was evaluated by comparison with 
conserved elements (phastCons 23) identified from multiple alignments of vertebrate 
genome sequences to human or mouse. Candidate enhancers were assigned the score of the 
highest-scoring phastCons element overlapping either the whole peak or the 1kb genomic 
interval centered on the peak maximum (Supplementary Table 5).
Human-mouse alignments and conservation
To identify human-specific candidate heart enhancers, we aligned the human candidate 
enhancers to the mouse genome (mm9) using the liftOver tool 40. We then analyzed the in 
vivo occupancy of p300/CBP in mouse and classified the human candidate enhancers as one 
of four classes: (class 1) human peaks mapped to the mouse genome, ≤2 kb apart from a 
mouse p300/CBP peak; (class 2) human peaks whose mouse homologous regions were not 
called as p300/CBP peaks but exceeded the genome-wide background (coverage threshold 
of 11 overlapping extended reads); (class 3) human peaks mapped to mouse regions with no 
p300/CBP binding; and (class 4) human peaks with no unique homologous locus in the 
mouse genome.
Transcription factor binding site analysis
Transcription factor binding site analysis of the top 500 acCBP/p300 peaks from human and 
mouse heart was performed as described previously 13,15
Transgenic mouse enhancer assay
We selected regions for in vivo testing from the 5,047 fetal human candidate heart enhancer 
data set based on their Grizzly peak score. The high scoring 65 in vivo tested sequences also 
include three elements (hs1913, hs1948, and hs1959) that were initially called by the Grizzly 
Peak Fitting algorithm, but subsequently removed from the final genome-wide data set by an 
increased-stringency filtering process. Enhancer candidate regions consisting of ∼3.7kb 
(Supplementary Table 10) of human genomic DNA flanking the p300/CBP peak were 
amplified by PCR from human genomic DNA (Clontech) and cloned into the Hsp68-
promoter-LacZ reporter vector as previously described 27,41. Genomic coordinates of 
amplified regions are reported in Supplementary Table 12. Transgenic mouse embryos were 
generated as previously described 41. Only patterns observed in at least three different 
embryos resulting from independent transgenic integration events of the same construct 
were considered reproducible 42. For histological analysis, embryos were embedded in 
paraffin and sectioned using standard methods.
The activity of 8 selected elements was tested in adult heart (4 weeks of age). These 
elements were selected based on the reproducibility of LacZ cardiac staining at e11.5 and 
the peak score in the adult human heart candidate enhancer data set. The transgenic mouse 
enhancer assays were carried out as detailed above, except that F0 transgenic mice were 
sacrificed at 4 weeks of age. Hearts were X-Gal stained and sectioned using standard 
methods. All animal work was performed in accordance with protocols reviewed and 
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approved by the Lawrence Berkeley National Laboratory Animal Welfare and Research 
Committee.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. ChIP-seq identification of candidate enhancer regions from human fetal and adult 
heart
Human fetal heart was obtained at gestational week 16, adult heart tissue was obtained from 
the septum of an adult failing heart. a) Overview of strategy and results of ChIP-seq 
analysis. 5,047 regions from fetal heart and 2,233 from adult heart were significantly 
enriched in p300/CBP binding and considered as candidate human heart enhancers (distal: 
>2.5kb from the nearest transcript start site; peaks <2.5kb from the nearest transcript start 
site were considered proximal/promoter-associated). b) Overlap of candidate enhancers 
identified in both fetal and adult heart tissues. c) ChIP-seq profiles of p300/CBP in the 
genomic region of the tested element hs1763 (thin black bar). Thick black bars indicate two 
regions of significant enrichment in p300/CBP binding, in introns of the INPP5A gene. Thin 
grey line represents read depth of 10, maximum read depth shown is 50.
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Figure 2. Human p300/CBP candidate enhancers are enriched near human heart-expressed 
genes
Frequency of human fetal heart candidate enhancers (red) compared to matched random 
regions (black), near genes that are (a) over-expressed and (b) under-expressed in fetal heart 
relative to other human tissues (see Methods). Errors bars indicate 95% confidence 
intervals.
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Figure 3. In vivo testing of predicted human heart enhancer activities in transgenic mice
a) In vivo enhancer activity of the 65 tested elements. b) Proportion of reproducible 
enhancers by extent of sequence constraint (+, phastCons > 350; -, phastCons ≤ 350). c) 
Proportion of reproducible enhancers by binding conservation to the mouse (+, p300/CBP 
binding significant or sub-significant but above background; -, p300/CBP binding at no 
more than genome-wide background levels or non-alignable peaks). n.s., not significant 
(pairwise comparison for each subcategory, two-tailed Fisher's Exact test, P > 0.05 in all 
cases).
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Figure 4. Activity of human cardiac enhancers in embryonic and adult transgenic mice
Examples of in vivo enhancer activities. In each panel from left to right: Whole-mount 
stained e11.5 embryo, close-up and histological section of heart at e11.5, whole-mount 
stained heart at postnatal day 28, longitudinal section of heart at postnatal day 28. All 
specimens were stained for LacZ enhancer reporter activity (dark blue). In each panel, 
element ID, reproducibility in e11.5 embryos and flanking genes are indicated. LV-left 
ventricle; RV-right ventricle; LA-left atrium; RA-right atrium; OFT-outflow tract; PA-
pulmonary artery; Ao-Aorta.
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Table 1
Top enriched annotations of putative target genes near the candidate human heart 
enhancers
Unsupervised enrichment analysis 20 of annotated genes in the proximity of p300/CBP distal regions. a) Top 
10 enriched Mouse Genome Informatics phenotype ontology terms 29, showing highly significant enrichment 
of genes implicated in cardiovascular-system related phenotypes. b) Top 5 terms in the biological process gene 
ontology (GO), showing highly significant enrichment of cardiovascular-related terms. Only terms that 
showed significant enrichment and had a binomial fold-enrichment of at least 2 were considered.
Top Enriched Phenotypes Binomial FDR Q-Val Binomial Fold Enrichment
1. abnormal cardiac muscle morphology 3.32E-44 2.1
2. abnormal vitelline vasculature 1.13E-31 2.2
3. abnormal epicardium morphology 5.23E-27 5.7
4. thin ventricular wall 3.43E-22 2.6
5. abnormal myocardial trabeculae morphology 7.74E-22 2.3
6. decreased cardiac muscle contractility 2.79E-21 2.3
7. abnormal renal glomerulus morphology 3.34E-21 2.1
8. anemia 1.14E-20 2.0
9. pericardial effusion 7.44E-20 2.9
10. abnormal cardiac muscle contractility 4.35E-19 2.1
Top Enriched GO Terms Binomial FDR Q-Val Binomial Fold Enrichment
1. blood vessel morphogenesis 2.37E-30 2.2
2. heart looping 5.19E-28 7.5
3. blood vessel development 7.73E-27 2.0
4. vasculature development 2.30E-26 2.0
5. regulation of heart contraction 3.76E-25 2.9
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